What is Parkinson’s disease?
Parkinson’s disease is a disorder of the nervous system. It results from damage to the nerve cells that produce dopamine, a chemical that is vital for the smooth control of muscles and movement.
What are the symptoms of Parkinson’s disease?
The main symptoms of Parkinson’s disease are:
- tremor or shaking, often when resting or tired. It usually begins in one arm or hand
- muscle rigidity or stiffness, which can limit movement and may be painful
- slowing of movement, which may lead to periods of freezing (inability to start moving) and small shuffling steps
- stooped posture and balance problems
What causes Parkinson’s disease?
Doctors do not yet know the cause of the disorder, and it’s thought to be inherited in only a small proportion of cases. Exposure to certain toxins in the environment is also thought to play a small role. Some cases of Parkinson’s disease appear to be hereditary, and a few cases can be traced to specific genetic mutations. While genetics is thought to play a role in Parkinson’s, in most cases the disease does not seem to run in families. Many researchers now believe that Parkinson’s results from a combination of genetic and environmental factors, such as exposure to toxins.
So, what does the research have to say about Beta Caryophyllene’s (BCP) potential to help PD sufferers?
One study stated that the cannabinoid type two receptors (CB2), an important component of the endocannabinoid system (ECS), have recently emerged as neuromodulators and therapeutic targets for neurodegenerative diseases including (PD). The downregulation of CB2 receptors has been reported in the brains of PD patients. Therefore, both the activation and the upregulation of the CB2 receptors are believed to protect against the neurodegenerative changes in PD.
It’s interesting to note that the ECS, consisting of cannabinoid receptors type 1 and 2 (CB1 and CB2), their endogenous ligands, and the enzymes for synthesis, reuptake and metabolism of the endocannabinoids, has emerged as an important neuromodulator system for many brain functions such as learning, memory, mood, addiction, and reward processing.
They concluded that:
The present study suggests that BCP has the potential therapeutic efficacy to elicit significant neuroprotection by its anti-inflammatory and antioxidant activities mediated by activation of the CB2 receptors.
They also stated:
Our findings clearly demonstrate that CB2 receptors may be an attractive therapeutic target for PD and BCP could be an attractive candidate molecule for the treatment of PD. Furthermore, BCP may be the first CB2 receptor agonist and plant derived cannabinoid to be developed in the quest for novel compounds that might improve conventional therapies as well as provide novel disease-modifying agents.
Another study showed:
The results showed that BCP inhibits oxidative stress-induced cell death of dopaminergic neurons…. at the same time as it enhances the expression and enzymatic activity…. Also, the BCP treatment ameliorated motor dysfunction and protected the dopaminergic cells ….. Accordingly, this phytocannabinoid may represent a promising pharmacological option to safeguard dopaminergic neurons and prevent the progression of PD.
What great news for those with PD. So once again, the activation of the CB2 receptors is paramount to health and healing – it’s great to know that Canna Oils BCP binds directly with these receptors. The snug lock and key fit ensures a strong and effective signal throughout the body.
Disclaimer: The information in this post is for reference purposes only and not intended to constitute or replace professional medical advice. Please consult a qualified medical professional before making any changes to your diet, medications or lifestyle. The above information is for educational purposes only – not intended as medical advice. Results vary person to person.